Cargando…

Management of asthma patients during the COVID-19 pandemic: pathophysiological considerations to address the challenges

BACKGROUND: The coronavirus disease 2019 (COVID-19) has become a serious global health issue, especially for people with pre-existing health conditions. Patients dealing with asthma are presumed to be at higher risk as COVID-19 may cause severe respiratory distress. MAIN BODY: From the initial stage...

Descripción completa

Detalles Bibliográficos
Autores principales: Tabassum, Tahani, Rahman, Ahsab, Araf, Yusha, Ullah, Md. Asad, Hosen, Mohammad Jakir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817645/
https://www.ncbi.nlm.nih.gov/pubmed/35155689
http://dx.doi.org/10.1186/s43088-022-00204-4
_version_ 1784645691098791936
author Tabassum, Tahani
Rahman, Ahsab
Araf, Yusha
Ullah, Md. Asad
Hosen, Mohammad Jakir
author_facet Tabassum, Tahani
Rahman, Ahsab
Araf, Yusha
Ullah, Md. Asad
Hosen, Mohammad Jakir
author_sort Tabassum, Tahani
collection PubMed
description BACKGROUND: The coronavirus disease 2019 (COVID-19) has become a serious global health issue, especially for people with pre-existing health conditions. Patients dealing with asthma are presumed to be at higher risk as COVID-19 may cause severe respiratory distress. MAIN BODY: From the initial stage of the pandemic, several clinical trials and studies have assessed the association between COVID-19 and asthma; however, no significant association was reported. This may be due to the fact that most of the asthma cases remained undiagnosed and overlapping respiratory features make it difficult to differentiate between these two diseases. The pathomechanism of the conditions and the immune response generated in response to the conditions suggest that the presence of any of the conditions is very likely to influence the presence or severity of the other condition. So far, no specific treatments are known for COVID-19; however, the use of plasma therapy and broad-spectrum antiviral drugs during the initial phase of the pandemic and widespread vaccination during the latter phase has given positive outcomes in reducing COVID-19 cases as well as disease severity. SHORT CONCLUSION: Taking asthma as an increased risk factor for COVID-19 morbidity, this article aims to provide comprehensive insights into the risk and proper management of asthma patients during this COVID-19 pandemic. The common medications of asthma patients suppress their respiratory immune response that might facilitate cytokine storm in COVID-19 patients. Similarly, there are risks of viral-induced asthma exacerbations. Besides, different social issues such as shortage of medicines, SDOH, and delayed clinical trials put asthma patients through inconvenience. The primary focus at this point should be to reduce probable asthma attacks and severity to prevent hospitalization of asthma patients. Moreover, for better management of asthma patients maintaining an asthma action plan and healthy lifestyle, ensuring a nutritious diet, and developing self-management interventions can play a crucial role.
format Online
Article
Text
id pubmed-8817645
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-88176452022-02-07 Management of asthma patients during the COVID-19 pandemic: pathophysiological considerations to address the challenges Tabassum, Tahani Rahman, Ahsab Araf, Yusha Ullah, Md. Asad Hosen, Mohammad Jakir Beni Suef Univ J Basic Appl Sci Review BACKGROUND: The coronavirus disease 2019 (COVID-19) has become a serious global health issue, especially for people with pre-existing health conditions. Patients dealing with asthma are presumed to be at higher risk as COVID-19 may cause severe respiratory distress. MAIN BODY: From the initial stage of the pandemic, several clinical trials and studies have assessed the association between COVID-19 and asthma; however, no significant association was reported. This may be due to the fact that most of the asthma cases remained undiagnosed and overlapping respiratory features make it difficult to differentiate between these two diseases. The pathomechanism of the conditions and the immune response generated in response to the conditions suggest that the presence of any of the conditions is very likely to influence the presence or severity of the other condition. So far, no specific treatments are known for COVID-19; however, the use of plasma therapy and broad-spectrum antiviral drugs during the initial phase of the pandemic and widespread vaccination during the latter phase has given positive outcomes in reducing COVID-19 cases as well as disease severity. SHORT CONCLUSION: Taking asthma as an increased risk factor for COVID-19 morbidity, this article aims to provide comprehensive insights into the risk and proper management of asthma patients during this COVID-19 pandemic. The common medications of asthma patients suppress their respiratory immune response that might facilitate cytokine storm in COVID-19 patients. Similarly, there are risks of viral-induced asthma exacerbations. Besides, different social issues such as shortage of medicines, SDOH, and delayed clinical trials put asthma patients through inconvenience. The primary focus at this point should be to reduce probable asthma attacks and severity to prevent hospitalization of asthma patients. Moreover, for better management of asthma patients maintaining an asthma action plan and healthy lifestyle, ensuring a nutritious diet, and developing self-management interventions can play a crucial role. Springer Berlin Heidelberg 2022-02-05 2022 /pmc/articles/PMC8817645/ /pubmed/35155689 http://dx.doi.org/10.1186/s43088-022-00204-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review
Tabassum, Tahani
Rahman, Ahsab
Araf, Yusha
Ullah, Md. Asad
Hosen, Mohammad Jakir
Management of asthma patients during the COVID-19 pandemic: pathophysiological considerations to address the challenges
title Management of asthma patients during the COVID-19 pandemic: pathophysiological considerations to address the challenges
title_full Management of asthma patients during the COVID-19 pandemic: pathophysiological considerations to address the challenges
title_fullStr Management of asthma patients during the COVID-19 pandemic: pathophysiological considerations to address the challenges
title_full_unstemmed Management of asthma patients during the COVID-19 pandemic: pathophysiological considerations to address the challenges
title_short Management of asthma patients during the COVID-19 pandemic: pathophysiological considerations to address the challenges
title_sort management of asthma patients during the covid-19 pandemic: pathophysiological considerations to address the challenges
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817645/
https://www.ncbi.nlm.nih.gov/pubmed/35155689
http://dx.doi.org/10.1186/s43088-022-00204-4
work_keys_str_mv AT tabassumtahani managementofasthmapatientsduringthecovid19pandemicpathophysiologicalconsiderationstoaddressthechallenges
AT rahmanahsab managementofasthmapatientsduringthecovid19pandemicpathophysiologicalconsiderationstoaddressthechallenges
AT arafyusha managementofasthmapatientsduringthecovid19pandemicpathophysiologicalconsiderationstoaddressthechallenges
AT ullahmdasad managementofasthmapatientsduringthecovid19pandemicpathophysiologicalconsiderationstoaddressthechallenges
AT hosenmohammadjakir managementofasthmapatientsduringthecovid19pandemicpathophysiologicalconsiderationstoaddressthechallenges